𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Use of the Thin Prep® Pap Test™ in clinical practice

✍ Scribed by Barbara J. Guidos; Suzanne M. Selvaggi

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
34 KB
Volume
20
Category
Article
ISSN
8755-1039

No coin nor oath required. For personal study only.

✦ Synopsis

Both methods were analyzed to compare specimen adequacy and detection rates of cervical lesions. The TP method reduced the ''satisfactory but limited by'' rate by 97% and the unsatisfactory rate by 63%. For low-grade squamous intraepithelial lesions (LSILs), TP slides yielded 3.6% (348/9,583) as compared to 0.98% (53/5,423) for CS, an increase of 267%. The TP method detected a threefold increase in the number of high-grade squamous intraepithelial lesions (HSILs) of 1.0% (100/9,583), as compared to 0.3% (17/5,425) for the CS group. The atypical squamous cells of undetermined significance/squamous intraepithelial lesion (ASCUS SIL) ratio was reduced by 54% in the TP group. In routine usage in our laboratory, the Thin Prep Pap Test yielded a significant increase in the detection of LSILs and HSILs as compared to conventional smears. Specimen adequacy was significantly improved.

📜 SIMILAR VOLUMES

Development, testing, and validation of
Development, testing, and validation of a patient satisfaction questionnaire for use in the clinical genetics setting
✍ Barbara Zellerino; Sharon A. Milligan; Ron Brooks; Debra L. Freedenberg; Dave S. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 2 views

## Abstract Patient satisfaction is an important component of assessing quality of care. The purpose of this study is to develop a concise patient satisfaction tool specifically for use in the clinical genetics setting. An international survey identified two domains, “Respect Given” and “Patient Qu

Consensus conference on the use of 90-yt
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology
✍ Umberto Vitolo; Giovanni Barosi; Stefano Fanti; Alessandro M. Gianni; Maurizio M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB

90-yttrium-ibritumomab-tiuxetan is approved for treatment of rituximab-relapsed/refractory CD201 follicular B-cell lymphoma and as consolidation therapy in untreated follicular lymphoma. Recommendations on the use of 90-yttrium-ibritumomab tiuxetan were issued in a consensus conference, sponsored by